Zacks.com on MSN5mon
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which ...
Hosted on MSN5mon
Longboard Pharmaceuticals Stock Soars 51%. It’s Being Bought for $2.6 Billion.
Pharmaceutical company Lundbeck will acquire Nasdaq-listed Longboard Pharmaceuticals in a $2.6 billion deal, the two companies said Monday. Denmark-listed H. Lundbeck will make a tender offer for ...
pharmaphorum2d
Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...
ADVFN1mon
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a ...
pharmaphorum5mon
Lundbeck planning for four novel drugs in phase 3 in 2026
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.
GlobalData on MSN12d
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Lundbeck has gained ODD from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to treat multiple system ...
Yahoo Finance16d
H. Lundbeck A/S (HLUN-B.CO)
Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment.
PharmaTimes5d
Taylor Boyd
Abzena has announced the appointment of Taylor Boyd to the newly created role of Chief Business Officer. Boyd joins the company from Longboard Pharmaceuticals, where he most recently served as Head of ...